

***Mycobacterium tuberculosis* Antigens:  
Evaluation of Immunodiagnostic Potential of  
Synthetic Peptides in Egyptian Patients**

A thesis submitted for the degree of

Master in Science by

***Ahmed Mahmoud Ahmed Ahmed Salman***

(B.Sc. Biochemistry, 2006)

**Under Supervision of**

***Prof. Dr. Ahmed Osman Egiza***

Professor of Biochemistry, Faculty of Science, Ain Shams University

***Prof Dr. Nabila A. El-Sheikh***

Professor of Microbiology and Immunology, Faculty of Medicine for Girls,  
Al-Azhar University

***Dr. Abdel-Rahman B. Abdel-Ghaffar***

Lecturer of Biochemistry, Faculty of Science, Ain Shams University

**Biochemistry Department**

**Faculty of Science**

**Ain Shams University**

**2011**

## مستضدات بكتيريا الدرن:

# تقييم قدرة التشخيص المناعي للبتيدات المخلقة في المرضى المصريين

رسالة مقدمة

للحصول على درجة الماجستير في العلوم

من الطالب

**أحمد محمود أحمد أحمد سالمان**

بكالوريوس العلوم في الكيمياء الحيوية

كلية العلوم - جامعة عين شمس

٢٠٠٦

تحت إشراف:

**أ.د. / أحمد عثمان عجيزه**

أستاذ الكيمياء الحيوية

قسم الكيمياء الحيوية

كلية العلوم - جامعة عين شمس

**أ.د. / نبيلة أنور الشيخ**

أستاذ الميكروبيولوجي و المناعة

كلية طب البنات - جامعة الأزهر

**د. / عبد الرحمن بدر الدين عبد الغفار**

مدرس الكيمياء الحيوية

قسم الكيمياء الحيوية

كلية العلوم- جامعة عين شمس

قسم الكيمياء الحيوية

كلية العلوم

جامعة عين شمس

٢٠١١

# **The Department Committee Agreement**

This thesis has not been submitted in  
this or any other university

*Ahmed Mahmoud Ahmed Ahmed Salman*

### **Biography**

Name: Ahmed Mahmoud Ahmed Ahmed Salman.

Date and place of birth: 15/8/1984, Cairo, Egypt.

Date of Graduation: May, 2006

Degree awarded: B.Sc. of Biochemistry, 2006.  
(Very good with honor degree).

Occupation: 3/2007

Date of Registration: 5/2009

## Table of Content

|                                                                                                   |      |
|---------------------------------------------------------------------------------------------------|------|
| TABLE OF CONTENT .....                                                                            | I    |
| TABLE OF TABLES .....                                                                             | VI   |
| TABLE OF FIGURES .....                                                                            | VIII |
| ACKNOWLEDGEMENT .....                                                                             | IX   |
| LIST OF ABBREVIATIONS .....                                                                       | XI   |
| ABSTRACT .....                                                                                    | XV   |
| INTRODUCTION .....                                                                                | 1    |
| AIM OF THE WORK .....                                                                             | 5    |
| REVIEW OF LITERATURE .....                                                                        | 6    |
| <b>MYCOBACTERIUM TUBERCULOSIS</b> .....                                                           | 6    |
| <u>THE BASICS OF CLINICAL BACTERIOLOGY</u> .....                                                  | 8    |
| <u>GENERATION TIME</u> .....                                                                      | 11   |
| <u>THE EPIDEMIOLOGY OF TUBERCULOSIS</u> .....                                                     | 11   |
| <u>INFECTION AND TRANSMISSION</u> .....                                                           | 13   |
| <u>RISK FACTORS FOR MYCOBACTERIUM TUBERCULOSIS INFECTION</u> .....                                | 14   |
| <u>FACTORS CONTRIBUTING TO THE RISE IN TB</u> .....                                               | 15   |
| <input type="checkbox"/> <i>HIV is accelerating the spread of TB</i> .....                        | 15   |
| <input type="checkbox"/> <i>Prisons</i> .....                                                     | 15   |
| <input type="checkbox"/> <i>Movement of people is helping the spread of TB</i> .....              | 16   |
| <input type="checkbox"/> <i>Poorly managed TB programs are threatening to make TB incurable</i> . | 17   |
| <input type="checkbox"/> <i>Smoking</i> .....                                                     | 17   |
| <input type="checkbox"/> <i>Obesity</i> .....                                                     | 18   |
| <u>RISK FACTORS FOR PROGRESSION OF INFECTION TO ACTIVE TUBERCULOSIS</u> .....                     | 18   |
| <u>EFFECTIVE TB CONTROL</u> .....                                                                 | 20   |
| <b>IMMUNOLOGY OF TB</b> .....                                                                     | 21   |
| <u>IMMUNE RESPONSE AGAINST MYCOBACTERIUM TUBERCULOSIS</u> .....                                   | 22   |
| <u>I. Innate Immune Response</u> .....                                                            | 23   |
| <input type="checkbox"/> Neutrophil leukocytes .....                                              | 23   |
| <input type="checkbox"/> Mast cells .....                                                         | 24   |
| <input type="checkbox"/> Macrophages .....                                                        | 25   |
| <input type="checkbox"/> Dendritic cells .....                                                    | 30   |
| <input type="checkbox"/> Natural killer cells .....                                               | 34   |
| <input type="checkbox"/> Epithelial cells .....                                                   | 35   |
| <u>II. Acquired Immune Response against M. tuberculosis</u> .....                                 | 36   |
| A. <u>Humoral immune response</u> .....                                                           | 37   |
| <u>Are antibodies protective against M. tuberculosis, an intracellular pathogen?</u> ..           | 39   |

|                                                                                       |           |
|---------------------------------------------------------------------------------------|-----------|
| B. <u>Cellular immune response</u> .....                                              | 41        |
| □ CD4 <sup>+</sup> T Cells.....                                                       | 41        |
| □ CD8 <sup>+</sup> T Cells.....                                                       | 42        |
| □ Gamma/delta T cells .....                                                           | 43        |
| □ Th17 cells.....                                                                     | 44        |
| <u>B AND T CELLS COLLABORATE TO REPEL INFECTIOUS CHALLENGE</u> .....                  | 45        |
| <u>T CELL ACTIVATION IS STRONGLY INFLUENCED BY B CELLS</u> .....                      | 46        |
| <u>CYTOKINES AND MYCOBACTERIUM TUBERCULOSIS</u> .....                                 | 48        |
| □ <u>Interferon Gamma (IFN<math>\gamma</math>)</u> .....                              | 48        |
| □ <u>Interleukin-4 (IL-4)</u> .....                                                   | 50        |
| □ <u>Interleukin-17 (IL-17)</u> .....                                                 | 51        |
| □ <u>Tumor Necrosis Factor-Alpha (TNF-<math>\alpha</math>)</u> .....                  | 53        |
| □ <u>Transforming Growth Factor-Beta (TGF-<math>\beta</math>)</u> .....               | 54        |
| <u>LATENCY AND MAINTENANCE OF THE IMMUNE RESPONSE</u> .....                           | 55        |
| <u>Resistance to Physical, Chemical, and Immunological challenges</u> .....           | 57        |
| □ M. tuberculosis detoxify lethal oxygen radicals.....                                | 58        |
| □ M. tuberculosis avoids, evades and even subverts innate and adaptive immunity ..... | 59        |
| □ M. tuberculosis modulates the host cell signaling pathways.....                     | 62        |
| <u>Cell migration and granuloma formation</u> .....                                   | 64        |
| <b>DIAGNOSIS OF TB.....</b>                                                           | <b>67</b> |
| <u>A. DIAGNOSTIC APPROACHES</u> .....                                                 | 67        |
| <u>1. Systemic symptoms and signs of tuberculosis</u> .....                           | 67        |
| □ Fever and sweating .....                                                            | 67        |
| □ Weight loss .....                                                                   | 68        |
| <u>2. Respiratory symptoms and signs of pulmonary tuberculosis</u> .....              | 68        |
| □ Cough .....                                                                         | 68        |
| □ Hemoptysis .....                                                                    | 69        |
| □ Dyspnea .....                                                                       | 69        |
| □ Thoracic pain .....                                                                 | 69        |
| □ Hoarseness .....                                                                    | 70        |
| <u>3. Radiological examination</u> .....                                              | 70        |
| <u>B. CONVENTIONAL DIAGNOSTIC METHODS</u> .....                                       | 70        |
| □ Introduction.....                                                                   | 70        |
| □ Specimen Handling .....                                                             | 71        |
| □ AFB Smear Staining.....                                                             | 72        |
| □ Adenosine Deaminase Activity.....                                                   | 73        |
| □ Culture .....                                                                       | 73        |
| <u>C. IMMUNOLOGICAL DIAGNOSIS</u> .....                                               | 75        |
| □ <u>Historical Overview</u> .....                                                    | 75        |
| a. Serological assays .....                                                           | 76        |
| □ <u>Enzyme Linked Immunosorbent Assay (ELISA)</u> .....                              | 76        |
| b. T cell based assays.....                                                           | 77        |
| i. <u>Tuberculin skin test</u> .....                                                  | 77        |
| ii. <u>Interferon-gamma determination</u> .....                                       | 78        |

## Table of Content

|                                                                         |            |
|-------------------------------------------------------------------------|------------|
| □ The Esat-6 system (ESX).....                                          | 81         |
| □ FDA-Approved Intended Use for IGRAs .....                             | 84         |
| <u>1. Enzyme-linked immunospot for interferon-gamma</u> .....           | 85         |
| <u>2. QuantiFERON-TB test</u> .....                                     | 85         |
| <u>D. NUCLEIC ACID AMPLIFICATION METHODS</u> .....                      | 89         |
| □ <i>In house methods for diagnosis of tuberculosis</i> .....           | 90         |
| <b>TUBERCULOSIS AND HIV/AIDS .....</b>                                  | <b>93</b>  |
| <b>TREATMENT OF TB .....</b>                                            | <b>95</b>  |
| <u>I. CHEMOTHERAPY OF TUBERCULOSIS</u> .....                            | 95         |
| <u>II. IMMUNOTHERAPY FOR TUBERCULOSIS</u> .....                         | 96         |
| <b>TB VACCINATION.....</b>                                              | <b>97</b>  |
| □ <u>CHALLENGES FOR TUBERCULOSIS VACCINE DEVELOPMENT</u> .....          | 97         |
| □ <u>M. TUBERCULOSIS VACCINATION APPROACHES</u> .....                   | 99         |
| <b>SUBJECTS AND METHODS.....</b>                                        | <b>103</b> |
| <u>SUBJECTS</u> .....                                                   | 103        |
| <u>BACTERIAL STRAIN</u> .....                                           | 106        |
| <u>PREPARATION OF CULTURE FILTRATE (CF)</u> .....                       | 107        |
| <u>Procedure</u> .....                                                  | 107        |
| <u>Reagents:</u> .....                                                  | 107        |
| <u>Equipments:</u> .....                                                | 107        |
| <u>Reagents preparation:</u> .....                                      | 107        |
| Middlebrook broth media: .....                                          | 107        |
| <u>Step by step protocol:</u> .....                                     | 108        |
| <u>SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS</u> .....                     | 109        |
| <u>Principle</u> .....                                                  | 109        |
| <u>Procedure:</u> .....                                                 | 111        |
| <u>Reagents:</u> .....                                                  | 111        |
| <u>Equipment:</u> .....                                                 | 111        |
| <u>Reagents preparation:</u> .....                                      | 112        |
| Acrylamide and N,N'-methylenebisacrylamide: .....                       | 112        |
| Sodium dodecyl sulfate (SDS) (10%):.....                                | 113        |
| Tris buffers for the preparation of resolving and stacking gels:.....   | 113        |
| i. Tris buffer for stacking gel (1 M, pH 6.8): .....                    | 113        |
| ii. Tris buffer for resolving gel (1.5 M, pH 8.8):.....                 | 113        |
| Ammonium persulfate (10%): .....                                        | 114        |
| Tris-glycine electrophoresis buffer:.....                               | 114        |
| Gel loading buffer (1 X): .....                                         | 115        |
| TEMED (N,N,N',N'-tetramethylethylenediamine): .....                     | 115        |
| <u>Step by step protocol:</u> .....                                     | 116        |
| <u>STAINING SDS-POLYACRYLAMIDE GELS WITH COOMASSIE BRILLIANT BLUE</u> . | 121        |
| <u>Procedure:</u> .....                                                 | 121        |
| <u>Reagents:</u> .....                                                  | 121        |
| <u>Preparations:</u> .....                                              | 121        |



## Table of Content

|                                                                         |     |
|-------------------------------------------------------------------------|-----|
| Coomassie Brilliant Blue dye: .....                                     | 121 |
| Destaining solution: .....                                              | 122 |
| <u>Step by step protocol:</u> .....                                     | 122 |
| Notes: .....                                                            | 123 |
| <u>Zn<sup>2+</sup> REVERSE STAINING TECHNIQUE</u> .....                 | 124 |
| <u>Procedure:</u> .....                                                 | 126 |
| <u>Reagents:</u> .....                                                  | 126 |
| <u>Preparations:</u> .....                                              | 126 |
| □ Equilibration solution (1X): .....                                    | 126 |
| □ Developer solution (1X): .....                                        | 126 |
| □ Storage solution for reverse-stained gels (1X): .....                 | 126 |
| <u>Notes:</u> .....                                                     | 126 |
| <u>Step by step protocol:</u> .....                                     | 127 |
| <u>Notes:</u> .....                                                     | 128 |
| <u>Destaining of zinc reverse stained gels technique:</u> .....         | 128 |
| <u>DETERMINATION OF PROTEIN CONTENT OF CULTURE FILTRATE BY FOLIN</u>    |     |
| <u>REAGENT</u> .....                                                    | 129 |
| <u>Procedure:</u> .....                                                 | 129 |
| <u>Reagents:</u> .....                                                  | 129 |
| <u>Equipments:</u> .....                                                | 129 |
| <u>Preparations:</u> .....                                              | 130 |
| Phosphate Buffer Saline (pH 7.4): .....                                 | 130 |
| Hydrochloric Acid (1N): .....                                           | 130 |
| Bovine Serum Albumin (BSA), 1% Freshly Prepared: .....                  | 130 |
| Sodium Hydroxide (0.1N): .....                                          | 130 |
| Sodium Carbonate (2%), Solution A: .....                                | 130 |
| Sodium Potassium Tartarate (1%): .....                                  | 131 |
| Copper Sulphate (0.5%), Solution B: .....                               | 131 |
| Solution C: .....                                                       | 131 |
| Working Solution of Folin Reagent, Freshly Prepared: .....              | 131 |
| <u>Step by step protocol:</u> .....                                     | 132 |
| <u>PURIFICATION OF 38 kDa ANTIGEN FROM THE CULTURE FILTRATE</u> .....   | 134 |
| <u>Procedure:</u> .....                                                 | 134 |
| <u>Reagents:</u> .....                                                  | 134 |
| <u>Equipments:</u> .....                                                | 134 |
| <u>Preparations:</u> .....                                              | 134 |
| Ammonium Bicarbonate (10 mM): .....                                     | 134 |
| <u>Step by step protocol:</u> .....                                     | 135 |
| <u>PURIFICATION OF 38 kDa ANTIGEN BY PASSIVE CHEMICAL ELUTION</u> ..... | 136 |
| <u>Procedure:</u> .....                                                 | 136 |
| <u>Reagents:</u> .....                                                  | 136 |
| <u>Equipments:</u> .....                                                | 136 |
| <u>Preparations:</u> .....                                              | 136 |
| Sodium Dodecyl Sulfate (SDS) (10%): .....                               | 136 |
| Gel Elution Buffer: .....                                               | 137 |
| <u>Step by step protocol:</u> .....                                     | 137 |
| <u>WHOLE BLOOD STIMULATION TECHNIQUE</u> .....                          | 138 |

## Table of Content

---

|                                                       |            |
|-------------------------------------------------------|------------|
| <u>PRINCIPLE:</u> .....                               | 138        |
| <u>PROCEDURE:</u> .....                               | 138        |
| <u>Equipments:</u> .....                              | 138        |
| <u>Antigens:</u> .....                                | 138        |
| <u>Specimen Collection and Preparation:</u> .....     | 139        |
| <u>Step by step protocol:</u> .....                   | 139        |
| <u>DETECTION OF SECRETED CYTOKINES BY ELISA</u> ..... | 141        |
| <u>(A) Human IFN<math>\gamma</math> ELISA</u> .....   | 141        |
| <u>Contents:</u> .....                                | 141        |
| <u>1. Principle:</u> .....                            | 141        |
| <u>2. Safety issues:</u> .....                        | 142        |
| <u>3. Materials and Reagents</u> .....                | 144        |
| <u>4. Method:</u> .....                               | 145        |
| <u>(B) Human IL-17 ELISA</u> .....                    | 149        |
| <u>Product Information</u> .....                      | 149        |
| <u>Description:</u> .....                             | 149        |
| <u>Components:</u> .....                              | 150        |
| <u>Other Materials Needed:</u> .....                  | 152        |
| <u>Time Requirements</u> .....                        | 153        |
| <u>Experimental Procedure</u> .....                   | 154        |
| <b>RESULTS</b> .....                                  | <b>156</b> |
| <b>DISCUSSION</b> .....                               | <b>186</b> |
| <b>CONCLUSION AND RECOMMENDATIONS</b> .....           | <b>199</b> |
| <b>SUMMARY</b> .....                                  | <b>200</b> |
| <b>REFERENCES</b> .....                               | <b>206</b> |

## **Table of Tables**

|                                                                                                                                                                          |     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 1: Lineage of the agents of TB. ....                                                                                                                               | 10  |
| Table 2: Amino acid sequences of synthetic overlapping peptides of ESAT-6 and CFP-10.....                                                                                | 83  |
| Table 3: Characterization of the tuberculin skin test and of the new blood tests.....                                                                                    | 88  |
| Table 4: Current major methods of TB diagnosis .....                                                                                                                     | 92  |
| Table 5: Major challenges and concerns for TB vaccine development. Modified from .....                                                                                   | 98  |
| Table 6: Demographic data of the healthy subjects and patients with pulmonary tuberculosis. ....                                                                         | 104 |
| Table 7: Effective Range of Separation of SDS-Polyacrylamide Gels .....                                                                                                  | 110 |
| Table 8: Solutions for Preparing Resolving Gels for Tris-glycine SDS-Polyacrylamide Gel Electrophoresis .....                                                            | 118 |
| Table 9: Solutions for Preparing 5% Stacking Gels for Tris-glycine SDS-Polyacrylamide Gel Electrophoresis .....                                                          | 120 |
| Table 10: Reading of protein content of culture filtrate and bovine serum albumin standard tubes.....                                                                    | 156 |
| Table 11: Statistical analysis of IFN $\gamma$ released in response to <i>M. tuberculosis</i> culture filtrate (CF) proteins in the studied groups. ....                 | 165 |
| Table 12: Multivariate statistical analysis of IFN $\gamma$ released in response to <i>MTB</i> culture filtrate (CF) in the studied groups compared to -TST group. ....  | 166 |
| Table 13: Multivariate statistical analysis of IFN $\gamma$ released in response to <i>MTB</i> culture filtrate (CF) in the studied groups compared to +TST group. ....  | 166 |
| Table 14: Statistical analysis of IFN $\gamma$ released in response to <i>M. tuberculosis</i> purified 38 kDa antigen in the studied groups. ....                        | 168 |
| Table 15: Multivariate statistical analysis of IFN $\gamma$ released in response to <i>MTB</i> purified 38 kDa antigen in the studied groups compared to -TST group..... | 169 |
| Table 16: Multivariate statistical analysis of IFN $\gamma$ released in response to <i>MTB</i> purified 38 kDa antigen in the studied groups compared to -TST group..... | 169 |
| Table 17: Statistical analysis of IFN $\gamma$ released in responses to <i>M. tuberculosis</i> ESAT-6 overlapping synthetic peptides mixture in the studied groups.....  | 171 |

|                                                                                                                                                                         |     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 18: Multivariate statistical analysis of IFN $\gamma$ released in response to <i>MTB</i> ESAT-6 Pepmix in the studied groups compared to -TST group.....          | 172 |
| Table 19: Multivariate statistical analysis of IFN $\gamma$ released in response to <i>MTB</i> ESAT-6 Pepmix in the studied groups compared to +TST group....           | 172 |
| Table 20: Statistical analysis of IL-17 released in response to <i>M. tuberculosis</i> culture filtrate (CF) proteins in the studied groups. ....                       | 175 |
| Table 21: Multivariate statistical analysis of IL-17 released in response to <i>MTB</i> culture filtrate (CF) in the studied groups compared to -TST group. ....        | 176 |
| Table 22: Multivariate statistical analysis of IFN $\gamma$ released in response to <i>MTB</i> culture filtrate (CF) in the studied groups compared to +TST group. .... | 176 |
| Table 23: Statistical analysis of IL-17 released in response to <i>M. tuberculosis</i> purified 38 kDa antigen in the studied groups. ....                              | 178 |
| Table 24: Multivariate statistical analysis of IL-17 released in response to <i>MTB</i> purified 38 kDa antigen in the studied groups compared to -TST group.....       | 179 |
| Table 25: Multivariate statistical analysis of IL-17 released in response to <i>MTB</i> purified 38 kDa antigen in the studied groups compared to +TST group.....       | 179 |
| Table 26: Statistical analysis of IL-17 released in response to <i>M. tuberculosis</i> ESAT-6 overlapping synthetic peptides mixture in the studied groups. ....        | 181 |
| Table 27: Multivariate statistical analysis of IL-17 released in response to <i>MTB</i> ESAT-6 Pepmix in the studied groups compared to -TST group.....                 | 182 |
| Table 28: Multivariate statistical analysis of IL-17 released in response to <i>MTB</i> ESAT-6 Pepmix in the studied groups compared to +TST group....                  | 182 |

## **Table of Figures**

|                                                                                                                                                |     |
|------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Figure 1: Schematic diagram of the multiscale model of antigen presentation .....                                                              | 33  |
| Figure 2: General outline of the ELISA procedure (Sandwich technique).....                                                                     | 76  |
| Figure 3: <i>M. tuberculosis</i> genome with six copies of IS6110.....                                                                         | 91  |
| Figure 4: Bovine Serum Albumin Standard Curve.....                                                                                             | 157 |
| Figure 5: SDS-PAGE of the Concentrated <i>M. tuberculosis</i> culture filtrate.....                                                            | 159 |
| Figure 6: Preparatory SDS-PAGE of the Concentrated <i>M. tuberculosis</i> Culture Filtrate Stained with Coomassie Brilliant Blue staining..... | 160 |
| Figure 7: Preparatory SDS-PAGE of the Concentrated <i>M. tuberculosis</i> Culture Filtrate Stained with Zn <sup>2+</sup> Reverse Staining..    | 162 |
| Figure 8: SDS-PAGE of the Purified 38 kDa and the 40 kDa Antigens .....                                                                        | 163 |
| Figure 9: IFN $\gamma$ response to <i>M. tuberculosis</i> culture filtrate proteins .....                                                      | 167 |
| Figure 10: IFN $\gamma$ response to <i>M. tuberculosis</i> purified 38 kDa antigen .....                                                       | 170 |
| Figure 11: IFN $\gamma$ response to <i>M. tuberculosis</i> ESAT-6 overlapping synthetic peptides mixture .....                                 | 173 |
| Figure 12: IL-17 response to <i>M. tuberculosis</i> culture filtrate proteins .....                                                            | 177 |
| Figure 13: IL-17 response to <i>M. tuberculosis</i> purified 38 kDa antigen .....                                                              | 180 |
| Figure 14: IL-17 response to <i>M. tuberculosis</i> ESAT-6 overlapping synthetic peptides mixtures.....                                        | 183 |
| Figure 15: IFN $\gamma$ response to <i>M. tuberculosis</i> antigens .....                                                                      | 184 |
| Figure 16: IL-17 responses to <i>M. tuberculosis</i> antigens.....                                                                             | 184 |
| Figure 17: Comparison between IFN $\gamma$ and IL-17 concentrations...                                                                         | 185 |

## **Acknowledgement**

**My deepest gratitude and thanks to God the most merciful for guiding me through, and giving me the strength to complete this work with the way it is, and peace upon the messenger of God Mohamed.**

I am deeply indebted to Prof. Dr. Ahmed Osman Egiza. Professor of Biochemistry, Faculty of Science, Ain Shams University, for helping me choosing the delightful subject of this work and for his endless support and sincere advice. It has been an honor and privilege to work under his generous supervision.

I would also like to express my sincere gratitude to Prof. Dr. Nabila Anwar El-Sheikh, Professor of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, for her close supervision, her patience, and continuous encouragement.

I wish to express my deepest thanks to Dr. Abdel-Rahman B. Abdel-Ghaffar, Lecturer of Biochemistry, Faculty of Science, Ain Shams University, for his guidance, valuable help, kind directions, generous support, friendly attitude and help during all of my research life.

I wish also to express my deepest gratitude to Prof. Dr. Peter Anderson, Director of Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark, for his valuable advices, support and for his donation of the ESAT-6 Antigen Peptide Mixture which strengthen the value of this work.

Words cannot suffice to express my gratitude to all my doctors. Without their patience, aid and great love, I would never been able to finish this work.

I would like to thank all the members of the Molecular Immunology Unit at the Microbiology Department, Faculty of Medicine for Girls, Al-Azhar University, for their continuous cooperation through this work.

Last but not least, I would like to thank all the staff of the Biochemistry Department, Faculty of Science, Ain Shams University and everyone who shared in the successfulness of this work by any means.

*Ahmed Mahmoud Ahmed Ahmed Salman*